© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
In this AJMC® Peer Exchange, experts offer perspectives on important issues facing managed care professionals in the evolving health care landscape.
August 4th 2022, 6:25pm
Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
July 28th 2022, 4:29pm
Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
July 18th 2022, 2:00pm
A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.
July 16th 2022, 1:10pm
Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.
July 12th 2022, 6:47pm
Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.
July 9th 2022, 12:16am
Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.
July 2nd 2022, 11:10am
Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.
July 1st 2022, 6:07pm
Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.
June 28th 2022, 8:29pm
Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.
June 28th 2022, 8:21pm
Professional experts offer suggestions on how payers can be further educated on RRMM treatment.